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Open access under the Ea b s t r a c t
The intravulvosubmucosal (IVSM) route has been used to reduce the dose of prosta-
glandin F2a (PGF2a), a luteolytic agent used in estrus synchronization programs. To
validate the effectiveness of PGF2a administered via IVSM, the estrus rate was
monitored in 1937 beef cows for 5 days (25.6% of estrus). The cows that did not show
signs of estrus by day 5 received 5 mg of dinoprost IVSM (1/5 of the standard dose;
n¼1440). By day 10, 68.2% of the cows were in estrus. In a second trial, using the same
synchronization protocol, the proportion of heifers in estrus after receiving 5 mg
dinoprost at day 5 via IVSM (47.4%; n¼97) or via an intramuscular injection (IM;
54.7%; n¼95) did not differ (P40.05). The occurrence of luteolysis (serum progesterone
concentrations below 1 ng/mL) was dependent on the period of the estrous cycle in
which the cows were treated with 5 mg of dinoprost via IM or IVSM. Luteolysis was
observed in 5 out of 10 cows treated at day 10 but was not observed in any cows treated
at day 5 of the estrous cycle. Luteolysis occurred in all animals treated with 25 mg
dinoprost independent of the estrous cycle period (day 5 or 10). After IVSM injection,
the PGF2a concentration did not differ in the uterine and jugular veins. This was further
conﬁrmed by measuring the concentration of 13,14-dihydro-15-keto-PGF2a (PGFM)
after the injection of 5 mg of dinoprost via the IM or IVSM route. Dinoprost IM and IVSM
injections resulted in a similar PGFM serum pattern over time, indicating the same rate
of absorption into the systemic circulation. Taking the results together, we concluded
that PGF2a IVSM injections reached the systemic circulation before reaching the ovary,
and the effectiveness of low doses of PGF2a was dependent on the period of the estrous
cycle and not on the route of administration.
& 2012 Elsevier B.V. Open access under the Elsevier OA license.a Maria,
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The luteolytic agent prostaglandin F2a (PGF2a) has
been used extensively to manipulate the estrous cycle in
cattle. Different routes of administration have been tested
in an attempt to reduce the dose administered (Alvarez
et al., 1991; Colazo et al., 2002a, 2002b), which has
resulted in estrus synchronization after intravulvosubmu-
cosal (IVSM) injection (Alvarez et al., 1991; Chohan, 1998;
Horta et al., 1986; Sun˜e et al., 1985), despite disagreement
M.T. Rovani et al. / Livestock Science 148 (2012) 60–66 61among different studies (Colazo et al., 2002b). In a
commercial context, our group synchronized more than
64,000 cows. We observed 79.8% of treated females in
estrus after the IVSM administration of 5 mg of dinoprost
(1/5 of the standard dose) using the 10-day, 1-injection
management system reported by Donaldson et al. (1982).
Brazil has the largest commercial herd in the world,
with approximately 205 million heads. Productivity in
heads per hectare has increased by 25% over the last 10
years (ABIEC, 2012). Hormonal protocols are widely used
in the management of bovine reproduction, and prosta-
glandin analogs are among the hormones used most
commonly to control the estrous cycle (for review see
Lamb et al., 2010). Prostaglandin F2a has been indicated
for both reproductive biotechniques and the treatment of
reproductive disorders (Alvarez et al., 1991; Colazo et al.,
2002a; Inskeep, 1973; Salasel and Mokhtari, 2011). There-
fore, it is essential to understand the mechanisms
involved in prostaglandin transport, metabolism and
luteolysis to further develop methods that are more
biologically efﬁcient and proﬁtable.
Some evidence indicates that an IVSM injection of
PGF2a reaches the ovaries independently of the systemic
circulation (Alvarez et al., 1991; Chohan, 1998; Gioso
et al., 2005; Horta et al., 1986; Sun˜e et al., 1985). The
establishment of the reproductive tract angioarchitecture
using contrasted radiography demonstrated many ana-
stomoses between vulvar and utero-ovarian vessels
(Ginther and Del Campo, 1974; Gioso et al., 2005). These
anatomic structures associated with the vascular counter-
current exchange mechanism between the ovarian artery
and the utero-ovarian vein could allow PGF2a injected via
the IVSM to avoid the systemic metabolism before reach-
ing the ovary. However, to our knowledge, there have
been no studies about the local mechanisms of PGF2a
administered via the IVSM route.
Studies of different routes and doses of PGF2a admin-
istration have evaluated the estrus response and serum
progesterone concentrations without considering the
responsiveness of the corpus luteum (CL) after treatment
(Alvarez et al., 1991; Chohan, 1998; Colazo et al., 2002a).
Thus, the aims of the present study were the following:
(1) to evaluate the effect of dose and administration route
on estrous behavior, (2) to assess the onset of luteolysis in
periods of low and high PGF2a responsiveness, and (3) to
determine the proﬁle of PGF2a and prostaglandin
metabolite concentrations (13,14-dihydro-15-keto-PGF2a;
PGFM) in the uterine and jugular veins after intramuscular
(IM) or IVSM administration of a reduced dose of PGF2a.
2. Materials and methods
2.1. Location, animals and feed
All protocols and procedures were approved by the
Institutional Committee for Ethics in Animal Experiments
at the Federal University of Santa Maria, RS, Brazil
(23081.008212/2010-68). The experiments were con-
ducted during the spring and summer in southern Brazil,
and all animals included in each experiment belonged to
the same farm. The local weather is humid subtropical,type CfA, in accordance with Ko¨ppen’s classiﬁcation. This
study included crossbred beef heifers and non-lactating
cows (Bos taurus taurus) with body condition scores of 3
and 4 (1¼extremely thin, 5¼very fat) (Houghton et al.,
1990). All animals were managed under an extensive
grazing system based on natural pastures and had free
access to a mineral supplement and water. The animals
used in the experiments involving estrous observation
were managed in groups with 300 or fewer animals.
Estrus detection was performed by visual observation
for 60 min twice a day.
2.2. Experiment 1. Effect of a reduced-dose PGF2a IVSM
injection on estrous behavior
Cycling, non-lactating beef cows (Bos taurus taurus) were
used to validate the efﬁciency of 5 mg (1/5 of the standard
dose) of dinoprost tromethamine (dinoprost; Lutalyse,
Pﬁzer Animal Health, S~ao Paulo, Brazil) via the IVSM in an
estrus synchronization system. Beef cows (n¼1937) were
synchronized with the 10-day, 1-injection management
system (Donaldson et al., 1982). Brieﬂy, estrus detection
was performed twice a day, at 12-h intervals for 5 d, which
was considered as the control period. In the morning of day
5, only the cows that were not considered to be in estrus
received a dose of 5 mg of dinoprost (IVSM; using a
21-gage, 2.5-cm needle). Estrous behavior was observed
for an additional 5 d, as described above.
2.3. Experiment 2. Intramuscular vs. intravulvosubmucosal
injection of PGF2a
Non-pregnant cyclic beef heifers (n¼251; 24–30
months old) were observed for estrous behavior twice a
day for 5 d. The animals considered not to be in estrus
during the ﬁrst 5 days received 5 mg of dinoprost and
were randomly placed in either the IM group (n¼95;
injection in the gluteal muscles using a 21-gage, 4-cm
needle) or the IVSM (n¼97) group. After treatment,
estrous behavior was observed and recorded for 5 d.
2.4. Experiment 3. PGF2a injection (IM or IVSM) at periods of
low and high corpus luteum sensitivity
Non-pregnant crossbred beef cows (n¼50) were
synchronized with progestagen intravaginal devices con-
taining 250 mg of medroxyprogesterone acetate and 2 mg
estradiol benzoate at day zero. The devices were main-
tained for 7 days, and 0.250 mg of cloprostenol sodium
(Ciosin; Intervet/Schering-Plough Animal Health, Cotia,
Brazil) was administered at the time of device removal.
Estrus detection was initiated at approximately 12 h after
intravaginal device removal and was performed twice a
day for 5 d. Thirty-eight cows were observed in estrus, and
twenty-six were used in the experiment. The animals
were randomly allocated to receive different doses of
dinoprost on day 5 after estrus (low PGF2a responsive-
ness): 25 mg IM, 5 mg IM, or 5 mg IVSM (n¼3/treatment);
or day 10 after estrus (high PGF2a responsiveness): 25 mg
IM (n¼3), 5 mg IM (n¼5), or 5 mg IVSM (n¼5). Two cows
at day 5 and two cows at day 10 of the estrous cycle were
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for progesterone analysis were collected by caudal veni-
puncture once a day for 5 d, starting at the time of the
dinoprost injection. Luteolysis was considered when the
serum progesterone concentration was lower than 1 ng/mL
4 days after treatment (Assey et al., 1993; Colazo et al., 2008).
2.5. Experiment 4. Systemic and uterine vein concentrations
of PGF2a and PGFM after IVSM administration
This experiment was performed to test the hypothesis
that PGF2a administered via the IVSM reaches the CL through
the systemic circulation. The uterine and jugular veins of a
crossbred beef cow without reproductive abnormalities were
cannulated according to the procedure described by Lewis
et al. (1977). Brieﬂy, the cow was fasted without access
to food and water for 12 h before the administration of
anesthesia and the surgical procedures. A vertical incision
was made in the left ﬂank to cannulate a branch of the
uterine vein at the hilus of the left ovary (Turner and
McIlwraith, 1989). The free end of a silicone tube (2mm
i.d. and 3.2 mm o.d.) was exteriorized through a small
incision in the ﬂank and maintained through the infusion of
heparinized saline. The jugular vein was also cannulated and
maintained by ﬂushing with heparinized saline (Lewis et al.,
1977). Treatments (saline or PGF2a) and blood collection
started 12 h after surgery. Onemilliliter of saline was injected
via the IVSM route (control treatment); after 3 h and 6 h, the
animal was treated with 5mg of dinoprost IVSM. These 3-h
intervals were necessary to completely clear PGF2a from the
systemic circulation (Ferreira and Vane, 1967). Blood was
collected from the jugular and uterine veins at the same time
by two different people immediately before each treatment
and every 5 min for 40 min. Additionally, blood samples
were collected after 120min of dinoprost injection to verify
the decrease in systemic and ovarian concentrations of PGF2a.
The samples were assayed for PGF2a.
The levels of prostaglandin metabolites were mea-
sured to investigate the effects of dose and route of
administration on the pulmonary metabolism of PGF2a
(Kindahl et al., 1976). The jugular vein of a crossbred beef
cow with normal estrous cycles was cannulated as
described. The cannulated cow was submitted to the
following treatments: 25 mg dinoprost IM, 5 mg dino-
prost IM, 5 mg dinoprost IVSM, and 1 mL saline IVSM. As
stated previously, a 3-h interval was allowed between
treatments. Blood samples were collected at 5-min inter-
vals over a 40-min period and were assayed for PGFM.
2.6. Blood sampling and hormone assays
Blood samples were collected and allowed to clot for
30 min at room temperature before centrifugation at
1500 g for 10 min at room temperature. Serum was
placed into cryogenic vials, frozen, and stored at 80 1C
for further analysis. Enzyme immunoassay kits (Cayman
Chemical Company, Ann Arbor, MI) were used to quantify
PGFM and PGF2a (Del Vecchio et al., 1992). The intra-
assay CV was 7.13% and 2.58%, respectively; sensitivity
was 0.015 and 0.010 ng/mL, respectively, for PGFM and
PGF2a. The electrochemiluminescence immunoassay(Roche, Brazil) was performed to determine serum pro-
gesterone concentrations (Bossaert et al., 2008). The intra-
and inter-assay CV were 2.09% and 1.23%, respectively.
2.7. Statistical analysis
All statistical analyses were performed using the SAS
software package (SAS Institute Inc., Cary, NC, USA). Data
are presented as the mean7SEM unless otherwise indicated.
A probability of Pr0.05 was considered statistically signiﬁ-
cant. The frequency of estrus for the different treatments was
analyzed using categorical data-analysis models (CATMOD
procedure), and the differences between groups were deter-
mined. The analyses of treatment effects on serum proges-
terone as well as changes in the systemic and local
concentrations of PGF2a over time were organized as split-
plot ANOVA data and analyzed using mixed models (Littell
et al., 1998). The model for a repeated-measures experiment
was as follows: gijk¼mþaiþtkþ(at)ikþeijk, where gijk is the
response at time k for animal j in treatment group i, m is the
overall mean, ai is a ﬁxed effect of treatment i, tk is a ﬁxed
effect of time k, (at)ik is the ﬁxed-interaction effect of
treatment i with time k, and eijk is random error at time k
for animal j in treatment i. The main effects of treatment
group, hour, and their interaction were determined. Differ-
ences between groups at each time point were assessed
using the estimate statement. Different covariance structures
were tested, and the one with the lowest Akaike’s informa-
tion criterion was used (AIC). Other continuous data were
submitted to an ANOVA using the GLM, and multiple
comparisons between groups were performed for the least
square-adjusted means using the LSMEANS function in SAS
statistical software, with the PDIFF option to request p-values
for differences.
3. Results
3.1. Experiment 1. Effect of reduced doses of IVSM PGF2a
administration on estrous behavior
The rate of detection of estrus in cows over the ﬁrst 5
days (control) was 25.6% (497 out of 1937). By ﬁve days
after the injection of 5 mg dinoprost via IVSM, 68.2% of
cows were considered to be in estrus (983 out of 1440)
(Fig. 1A). For the entire period of estrus detection (10
days), a total of 76.4% of cows presented estrus. The rate
of estrus from days 1 to 6 was approximately 5% per day
(from 4 to 6%); this value increased to 7.9% at day 7 and
peaked at 19.9% on day 8 (3 days after prostaglandin
injection; Po0.05). This distribution of estrus revealed
that the cows were cycling at the beginning of the
experiment and that 5 mg of PGF2a (1/5 of the standard
dose) resulted in the induction of estrus (Fig. 1B).
3.2. Experiment 2. Intramuscular vs. intravulvosubmucosal
injection of PGF2a
Before treatment, heifers were observed for estrous
behavior for 5 d; at the end of this period, 23.5% of cows
were detected to be in estrus (4.7% per day as expected in
a cyclic herd). Treatment with 5 mg of dinoprost via IM or
Fig. 1. (A) Proportion of cows showing estrous behavior before (n¼1937)
and after treatment with 5 mg of dinoprost tromethamine via the
intravulvosubmucosal (IVSM) route at day 5, using the 10-day, 1-injection
management system. Only cows that were not considered to be in estrus
(n¼1440) were treated at day 5. (B) The distribution of estrous behavior
among cyclic beef cows (n¼1937) before and after injection with 5 mg of
dinoprost via IVSM at day 5. Asterisks (*) indicate signiﬁcant differences
(Pr0.01), and arrows (k) indicate the day of treatment.
Fig. 2. Proportion of cyclic beef heifers showing estrous behavior before
(control; n¼241) and after treatment with 5 mg of dinoprost trometha-
mine via the intravulvosubmucosal (IVSM) or intramuscular (IM) route
at day 5 using the 10-day, 1-injection management system. Only heifers
that were not considered to be in estrus were treated with 5 mg of
dinoprost via the IM (n¼95) or IVSM (n¼97) route at day 5. Asterisks (*)
indicate signiﬁcant differences (Pr0.01).
Fig. 3. Mean serum progesterone concentration (ng/mL) after the admin-
istration of dinoprost tromethamine on day 10 of the estrous cycle via the
intravulvosubmucosal (IVSM) or intramuscular (IM) route. The animals in
the control group were at the same stage of the estrous cycle as the treated
animals but were not submitted to any treatment. The asterisk (*) indicates
signiﬁcant differences from the control group (Pr0.05).
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respectively, during the 5 days after PGF2a administration
(Fig. 2; P40.05).
3.3. Experiment 3. PGF2a injection (IM or IVSM) at times of
low and high corpus luteum sensitivity
Prostaglandin F2a was injected in 22 beef cows at three
doses (0, 5, and 25 mg) using two routes of administration
(IM or IVSM) on one of two days of the estrous cycle (day
5 or 10). The pattern of serum progesterone concentration
differed in accordance with the dose or day of the estrous
cycle but was not affected by administration route. A
sharp decline in serum progesterone concentration (less
than 1 ng/mL 24 h after treatment) was observed only in
the 25-mg dose group (Po0.01). The data obtained from
animals that received 5 mg of dinoprost by IM or IVSM
injection (n¼3/treatment) at day 5 of the estrous cycle
(low PGF2a responsiveness period) are not shown because
the CL did not undergo luteolysis (4 days after treatment
serum, progesterone concentrations were Z5 ng/mL).
Animals treated at day 10 of the estrous cycle showed
lower progesterone concentrations than those in the control
group (Po0.05). However, luteolysis (serum progesterone
concentrations below 1 ng/mL) was observed in only 3 out of
5 cows (IM) and in 2 out of 5 cows (IVSM) treated with 5mg(Fig. 3). The serum progesterone concentrations were not
different in cows that did not have luteolysis or in controls
4 days after treatment (data not shown). All cows that
received 25mg IM (standard dose) at day 5 (n¼3) and day
10 (n¼3) underwent luteolysis.
3.4. Experiment 4. Systemic and uterine vein concentrations
of PGF2a and PGFM after IVSM administration
The concentrations of PGF2a did not differ in the jugular
and uterine veins after saline or PGF2a (5 mg) IVSM injections
(Fig. 4A). The concentrations of PGF2a in the jugular and
uterine veins after dinoprost treatment via the IVSM ranged
from 0.392 to 1.163 ng/mL, respectively. As expected, after
saline treatment, the concentrations of PGF2a were less than
0.120 ng/mL. In blood samples collected after 120min of
dinoprost treatment, serum PGF2a concentrations in the
Fig. 4. (A) Mean serum prostaglandin F2a (PGF2a) concentrations
(ng/mL) in the uterine and jugular veins after treatment with 5 mg of
PGF2a (dinoprost tromethamine) or saline via the intravulvosubmucosal
(IVSM) route. Before treatment, the cow was injected IVSM with 1 mL of
saline (control) to evaluate systemic and ovarian concentrations of
PGF2a for 40 min. (B) Serum 13,14-dihydro-15-keto-PGF2a (PGFM) con-
centrations (ng/mL) in the jugular vein after intramuscular injection of
saline (IM; control); 5 mg of dinoprost (IM or IVSM); and 25 mg of
dinoprost (IM).
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respectively. We also demonstrated that the concentration
of the PGF2a metabolite (PGFM) had a similar pattern after
the administration of 5 mg of dinoprost via IM or IVSM
(Fig. 4B). However, the PGFM pattern was greater with
25-mg IM injection compared to the other treatments.
4. Discussion
The most important ﬁndings in our study were the
following: (1) 1/5 of the standard dose of PGF2a was
effective in synchronizing estrous behavior in a large
number of animals when injected in cows after day 5 of
the estrous cycle by either the IM or IVSM routes; (2) the
effectiveness of PGF2a in inducing luteolysis was dependent
of the dose and period of the estrous cycle, regardless of the
route; (3) PGF2a concentrations in the jugular and uterineveins were not different after the IVSM injection of 5 mg of
dinoprost; and (4) the PGF2a metabolite (PGFM) concentra-
tion over time was not route dependent but was dose
dependent.
Many cows (n¼1937) were synchronized with PGF2a
via IVSM injection (5 mg dinoprost) using the 10-day,
1-injection management system (Donaldson et al., 1982).
This synchronization system is a good model with which
to study the route of PGF2a injection. Animals were
monitored twice a day for 5 days to determine their
estrous cyclicity. Over the ﬁrst 5 d, 5.1% of the cows
showed estrous behavior, which conﬁrmed that many of
the cows were cycling. On the morning of the ﬁfth day of
attempts at estrus detection, dinoprost (5 mg) was admi-
nistered via the IVSM route. A peak of estrous behavior
was observed 3 days after PGF2a injection. This estrus
proﬁle validated the luteolytic efﬁciency of the reduced
dose of PGF2a. Low doses of PGF2a and alternative routes
of administration have been used extensively by veter-
inary practitioners in order to reduce costs (Colazo et al.,
2002a, 2002b; Horta et al., 1986; Inskeep, 1973; Louis
et al., 1974). With this aim, IVSM has been the route of
choice when using low-dose PGF2a as a luteolytic agent,
mainly in attempts to synchronize estrus among cattle
(Alvarez et al., 1991; Chohan, 1998; Horta et al., 1986;
Ono et al., 1982; Sun˜e et al., 1985).
The local vascular countercurrent of PGF2a transport
from the uterine venous blood to the ovarian arterial
blood is well established (Barrett et al., 1971; Hixon and
Hansel, 1974; Land et al., 1976; McCracken et al., 1972,
1981). Recently, it has been demonstrated that the trans-
port of PGF2a from the uterus to the ovary is regulated by
PGF2a transporter protein-mediated mechanisms at the
time of luteolysis (Lee et al., 2010). Thus, the IVSM route
has been used based on the hypothesis that PGF2a would
reach the ovary, avoiding pulmonary clearance. Conse-
quently, a low dose of PGF2a would be enough to induce
luteolysis. However, in the second experiment, we
demonstrated that 5 mg of PGF2a (1/5 of the standard
dose) administered IM or IVSM in heifers resulted in
similar rates of estrous behavior, as reported by Alvarez
et al. (1991). The distribution pattern of cows in estrus
was similar to that observed in the ﬁrst experiment, and
the heifers were also cyclic (4.7% of estrus per day in the
ﬁrst 5 d). Combining the results of both routes (IM and
IVSM), the estrus rate was 16% three days after the
administration of 5 mg of dinoprost, as expected after
PGF2a treatment in the 10-day, 1-injection management
system (Donaldson et al., 1982). The number of animals in
estrus peaked at day 8, indicating that the 5 mg of
dinoprost administered via the IM and IVSM routes
induced luteolysis at the same rate. This ﬁnding provides
indirect evidence that PGF2a given via the IVSM route is
absorbed and reaches the ovary through the systemic
circulation rather than through any local communication
system.
For the past 30 years, there has been controversy about
the rationale of using reduced doses of PGF2a via the IVSM
route (Alvarez et al., 1991; Chohan, 1998; Colazo et al.,
2002b). A low dose of PGF2a is required when it is infused
throughout the uterus (Louis et al., 1974; Tervit et al.,
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Furthermore, a low dose of PGF2a administered through
the IVSM route was as efﬁcient as the recommended IM
dose in inducing labor in swine (Friendship et al., 1990).
The stage of the CL might be related to the effectiveness of
5 mg of dinoprost administered via the IVSM route in
inducing luteolysis. For this reason, we tested the hypoth-
esis that the CL was less sensitive to the low dose of PGF2a
during the early stages of its formation. Cows treated with
reduced doses during a period of lower CL sensitivity (day
5 of the estrous cycle) did not exhibit functional luteolysis
regardless of the administration route (IM or IVSM). Lack
of luteolytic effect was also reported when low doses of
PGF2a were administered subcutaneously or IM at day 5
or 7 of the estrous cycle (Berardinelli and Adair, 1989;
Colazo et al., 2002a). However, in this study, luteolysis
occurred in 5 out of 10 cows treated with 5 mg (IVSM or
IM) at day 10 of the estrous cycle. In contrast, all animals,
regardless of the timing (day 5 or 10), responded to a
25-mg injection of dinoprost. Additionally, cows treated
at day 5 with 5 mg IM or IVSM showed a serum proges-
terone concentration of 6.470.3 ng/mL 4 days after
treatment; these values are normally observed at day 9
of the estrous cycle (Stabenfeldt et al., 1969). Conse-
quently, the age of the CL has to be considered as an
important factor that inﬂuences the effectiveness of a
reduced dose of PGF2a (Alvarez et al., 1991; Chohan,
1998; Colazo et al., 2002a).
Blood serum samples obtained from the jugular and
uterine veins were used to determine whether the
injected PGF2a was reaching the ovaries through the
systemic or the ovarian circulatory pathway (Hixon and
Hansel, 1974; Lewis et al., 1977). The surgery for uterine
vein cannulation was extremely invasive. Due to animal
welfare considerations, only one animal was cannulated.
Using the same approach, Hixon and Hansel (1974)
demonstrated that PGF2a administered in an intrauterine
fashion was transferred from the uterus to the ovarian
artery before reaching the systemic circulation in cattle.
Despite the countercurrent mechanism and the vascular
anatomy between the vulva and the uterus, our results
indicated that there was no noteworthy local transfer of
PGF2a from the IVSM to the ovaries. Therefore, we tested
the hypothesis that PGF2a injected via the IVSM reaches
the CL through the systemic circulation. The concentra-
tions of PGF2a did not differ in the jugular and uterine
veins over time when dinoprost was injected via IVSM.
The pattern of PGFM in the jugular vein (an indicator
of PGF2a release into the circulation) (Kindahl et al., 1976)
was similar over time after treatment with 5 mg of
dinoprost via either the IM or IVSM route. These results
provide further evidence that PGF2a reaches the circula-
tory system before the ovary and support the absence of a
route (IM or IVSM) effect. The goal of this experiment was
to conﬁrm the results from a PGF2a experiment using a
less invasive approach. Despite the use of a single cow, all
results from the current study (estrous behavior, PGF2a
and PGFM concentrations) are in agreement and clearly
demonstrated that PGF2a reached the systemic circulation
before reaching the ovary after administration through
the IVSM route.In summary, this is the ﬁrst study that investigated the
PGF2a pathway (systemic or local circulation) after IVSM
PGF2a treatment. We also demonstrated with a large
number of animals that the dose of PGF2a could be
reduced when using the 10-day, 1-injection management
system. The IVSM route could be useful to avoid the
muscle tissue damage caused by dinoprost (Fajt et al.,
2011) when applied in commercial systems. Furthermore,
the reﬂux of a small volume (1 mL) is more likely when
administering the drug through the IM route when
compared to the IVSM route. However, the IVSM is not
as practical as IM administration in a large number of
animals. In conclusion, PGF2a injected via IVSM reached
the systemic circulation before reaching the ovary. These
data also demonstrated that the luteolytic effectiveness of
reduced doses of dinoprost is mainly dependent on the
period of the estrous cycle and is not affected by IVSM or
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